Rostrum® Tablets

Oral tablet.

Broad-spectrum antimicrobial.

Each tablet contains:
Enrofloxacin…………………………………. 50 mg
Excipients c.s.p…………………… 1 tablet

Rostrum® is a broad-spectrum antibacterial, recommended for the treatment of:

• Gastrointestinal tract infections (Escherichia coli, Salmonella spp., Proteus spp.).
• Respiratory tract infections (Pasteurella spp., Bordetella spp., Klebsiella spp.).
• Genitourinary infections such as nephritis, pyelonephritis, cystitis. (Escherichia coli, Corynebacterium pyogenes, Staphylococcus aureus, Streptococcus spp. and Pseudomonas aeruginosa).
• Skin infections.
• Ear canal infections and otitis (Escherichia coli, Staphylococcus aureus, Streptococcus spp. and Pseudomonas aeruginosa).
• Dermatitis, infected wounds (Escherichia coli, Klebsiella spp., Staphylococcus aureus, Streptococcus Spp. and Pseudomonas aeruginosa).

Administer directly into the oral cavity.

1 tablet of 50 mg/10 kg body weight per day, for 7 to 10 days, equivalent to 5 mg/kg body weight/day/for 7 to 10 days.
Half the dose may be given, twice a day.

Dogs and cats.

• Enrofloxacin is contraindicated in animals with hypersensitivity to quinolones.
• Do not administer to small to medium breed dogs, less than 1 year old, or large breed dogs less than 1 1/2 years old.
• Do not administer to cats under 8 weeks of age.
• The use of Enrofloxacin may cause the formation of crystals in urine, so it is recommended not to administer it in dehydrated animals.
• It is not recommended for use during pregnancy and/or breastfeeding.

• Arthropathies have been reported in immature animals, especially dogs. The risk of arthropathy increases when the dose is increased, however, it has also been reported when recommended doses are used in dogs.
• Other adverse effects that have been reported in very rare cases (less than 1 animal in 10,000 animals, including isolated reports) include vomiting, anorexia, increased liver enzymes, ataxia, seizures, depression, lethargy, and nervousness

• Keep out of reach of children and pets.
• Fluoroquinolones, such as Enrofloxacin, should not be used as a first line of treatment, unless no therapeutic alternative is available. When used as a second treatment, it should be on the basis of susceptibility studies.
• For Costa Rica: This product may cause antimicrobial resistance.

Compounds containing di- or trivalent cations such as aluminum, calcium, magnesium, iron, or zinc may decrease the absorption of Enrofloxacin. Thus, for example, antacids containing cations (Mg2+, Al3+, Ca2+) can bind to enrofloxacin and prevent its absorption.
Sucralfate may inhibit the absorption of enrofloxacin. It is recommended to separate both dosages for at least two hours.
Enrofloxacin given with Theophylline may increase your serum levels. In dogs, theophylline clearance was reduced by 43% when co-administered with enrofloxacin at doses of 5 mg/kg every 24 hours.
Concomitant administration with other drugs that have hepatic metabolism may affect the pharmacokinetics of one or both drugs.

Store at room temperature below 30°C. Do not refrigerate or freeze.

Dispose of unused product residues in their original packaging. Dispose of waste of this product with caution along with household waste.

• For Chile: Sale under prescription Veterinary doctor retained.
• For Export: Sale under prescription Veterinary Doctor.

VETERINARY USE

Chile: Reg. SAG N° 602
Rep. Dominican:Reg. No. 8786
Bolivia: Reg. SENASAG PUV-F N° 007250/16
Costa Rica: Reg. No. MV-5759
Peru: SENASA Registry F.82.21.I.0385

Box with 10 tablets.

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.